Search results
Chest Radiograph Screening for Detecting Subclinical Tuberculosis in Asymptomatic Household...
Centers for Disease Control and Prevention· 2 hours agoDetecting Subclinical Tuberculosis, Peru
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...
KTLA-TV Los Angeles· 15 hours agoUCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX ...
Celltrion USA announces two-year data for ZYMFENTRA™(infliximab-dyyb) to be presented at Digestive...
FOX 5 San Diego· 7 days agoCelltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients with moderately to severely active ...
Addison's disease: Symptoms, causes, treatment, and more
Medical News Today· 3 days agoAddison’s disease occurs when the adrenal glands do not produce enough of two steroid hormones...
Disease infected ticks are looking to bite. How people can stay safe
Gannett via AOL· 7 days agoWear sneakers or boots, not sandals. Tie back long hair or wear a hat. Consider using insect...
A case of tuberculosis was detected at a Chester County school. Here's what officials say.
The Post and Courier· 6 days agoThe S.C. Department of Health and Environmental Control sent a letter to parents that day about the...
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved...
WTRF Wheeling· 3 days agoIn Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure ...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 4 days ago...2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients with moderately to severely active ulcerative colitisa (UC) receiving subcutaneous (SC) TREMFYA® (guselkumab) 200 mg every...
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease...
WFRV 5 Green Bay· 7 days ago...from the SEQUENCE head-to-head trial comparing risankizumab (SKYRIZI®) versus ustekinumab (STELARA®) in Crohn's disease include an economic analysis and oral presentation that assessed inflammation biomarkers - Additional presentations include efficacy and safety data evaluating clinical,...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 3 days agoTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO),today announced the availability of SIMLANDI (adalimumab-ryvk) ...